Autologous Peripheral Blood Hematopoietic Cell Transplantation in Dogs with T-Cell Lymphoma
| Autor: | Steven E. Suter, E. E. Warry, Jennifer L. Willcox |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Male
medicine.medical_specialty Bone marrow transplantation Cyclophosphamide CD34 Lymphoma T-Cell Transplantation Autologous Peripheral blood mononuclear cell Gastroenterology Dogs Total body irradiation Internal medicine Pulmonary fibrosis medicine Animals T-cell lymphoma Dog Diseases General Veterinary business.industry Hematopoietic Stem Cell Transplantation Engraftment medicine.disease Standard Articles Surgery Lymphoma Transplantation Treatment Outcome Blood Component Removal Original Article Female Apheresis business CD34+ Whole-Body Irradiation medicine.drug |
| Zdroj: | Journal of Veterinary Internal Medicine |
| ISSN: | 0891-6640 |
| Popis: | Background Peripheral blood CD34+ hematopoietic cell transplantation (PBHCT) is commonly used to treat human patients with relapsed non-Hodgkin diffuse, large B-cell lymphoma with cure rates approaching 50%. Objective To determine the safety and feasibility of performing PBHCT to treat canine B-cell lymphoma (LSA) patients in a clinical academic setting. Animals Twenty-four client-owned dogs diagnosed with B-cell LSA. Methods After high-dose cyclophosphamide and rhG-colony-stimulating factor treatment, peripheral blood mononuclear cells were collected using cell separator machines. The harvested cells then were infused after a 10 Gy dose of total body irradiation (TBI). Post-irradiation adverse effects were managed symptomatically and dogs were discharged upon evidence of engraftment. Results More than 2 × 106 CD34+ cells/kg were harvested in 23/24 dogs. Preapheresis peripheral blood monocyte count was correlated with the number of CD34+ cells/kg harvested. Twenty-one of 24 (87.5%) dogs engrafted appropriately, whereas 2 dogs (8.3%) died in the hospital. One (5%) dog exhibited delayed engraftment and died 45 days after PBHCT. One dog developed presumed TBI-induced pulmonary fibrosis approximately 8 months after PBHCT. The median disease-free interval and overall survival (OS) of all dogs from the time of PBHCT was 271 and 463 days, respectively. Five of 15 (33%) dogs transplanted before they relapsed remain in clinical remission for their disease at a median OS of 524 days (range, 361–665 days). Conclusions and Clinical Importance In most cases, PBHCT led to complete hematologic reconstitution. Therefore, PBHCT may be considered as a treatment option for dogs with B-cell lymphoma. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text